Morning Market Snapshot: Small‑Caps and Bio Tools Jockey for Attention

October 7, 2025

DENVER, Colo., Oct 07, 2025 (247marketnews.com)- Small-caps are seeing early‐day action as a mix of cash raises, pipeline expansion, and new tech breakthroughs drive speculation today.

NUBURU (NYSE:BURU) is in focus after completing a $12 million public offering intended to fund acquisitions. One target is TEKNE S.p.A., providing defense and electronic warfare solutions. The company also formed a new defense division, Nuburu Defense LLC, and is pursuing further acquisition of assets in operational resilience and electronic warfare.

Kraig Biocraft Laboratories (OTCQB:KBLB) is commanding buzz after announcing that it has unlocked mass production of spider silk via genetically engineered silkworms. This long‑sought breakthrough solves what the company calls a “centuries‑old problem”: real spiders can’t be farmed due to loneliness, territoriality, and cannibalism. With this scalable platform, KBLB may soon make spider silk commercially viable across industries from biomedical to defense and textiles.

Processa Pharmaceuticals (NASDAQ:PCSA) remains under the spotlight following a large licensing deal with Intact Therapeutics for its compound PCS12852, which treats gastroparesis and GI motility disorders. The deal could deliver over $450 million in milestones plus royalties for Processa. The company also closed a $5 million public offering earlier this year to support its R&D efforts.

Bluejay Diagnostics (NASDAQ:BJDX) is advancing its SYMON‑II trial aimed at validating an IL‑6‑based sepsis mortality predictor. Key in its update: an amended supply agreement with Toray Industries extending cartridge manufacturing timelines, cash runway constrained but bolstered via recent financing, and manufacturing partnerships being prepped for regulatory submission.

Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) posted some mixed but interesting results: losses persist, but its schizophrenia treatment brilaroxazine continues to show promise in safety and efficacy profiles. The company has also raised cash via offerings, and analysts are watching whether Reviva can maintain momentum toward its pipeline deadlines.

For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com

Please click here to read the full Kraig Labs analyst report on 247marketnews.com.

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BURU, KBLB, PCSA, BJDX, RVPH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.